Back to search


KVAL: Scalable directional pump-less perfusion (dPP) organ -on-a-chip platform

Alternative title: Skalerbar retningsbestemt pumpeløs perfusjon (dPP) organ-on-a-chip plattform

Awarded: NOK 0.50 mill.

Project Manager:

Project Number:


Project Period:

2021 - 2022

Funding received from:


Subject Fields:

The World Economic Forum has listed the organ-on-a-Chip (OoC) technology as one of the top 10 emerging technologies in 2016. It has the potential to revolutionize drug screening, personalized drug testing and basic understanding of diseases by combining microbiology and microengineering on devices the size of a smartphone or smaller. A key aspect is to model human organ representations ?on chip? to be able to reliably interrogate their function and functional response. For this, it is crucial to create a biocompatible chip environment. Recently, we developed an innovative next-generation OoC platform that supports organ representations and directional circulation of oxygenized liquid resembling aspects of blood. The system is easy to use and at the same time, it allows developing complex tissue and organ representations. This commercialization project focuses on technical optimizations of the OoC platform in order to make it suitable it for a broad range of human organ representations. It prepares the ground for a versatile, scalable commercially viable platform.

As proposed, we achieved a Technology Readiness Level (TRL) of 4 (technology validated in the lab) which is an important step to bringing the innovation closer to the market. We also started the development of further biological use-cases to showcase the potential of the platform. We are now starting to reach out to colleagues from academia to present the platform to a broad audience and to get valuable feedback from our peers. We believe that the flexibility, ease-to-use, scalability, and good optical properties of our platform have a clear competitive advantage in the Organ-on-a-Chip arena and thus might help to improve preclinical testing for the advantage of patients and reduce animal experimentation.

Funding scheme: